Literature DB >> 20668958

Cryptogenic organizing pneumonia due to amiodarone: long-term follow-up after corticosteroid treatment.

Katja Schindler1, Wolfgang Schima, Josef F Kaliman.   

Abstract

Cryptogenic organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia) is a clinicopathological entity with characteristical radiographic findings such as bilateral, asymmetrical, sometimes migrating, patchy infiltrates in chest radiograph and ground-glass opacities in computed tomography. The disease has been observed in the context of gastrointestinal disorders, certain lung infections, autoimmune-mediated diseases (such as Wegener granulomatosis), inhalation of toxic fumes, bone marrow transplantation and administration of drugs. The benzofuran amiodarone, a commonly used antiarrythmic drug for atrial fibrillation, can exhibit several pulmonary adverse effects, amongst them cryptogenic organizing pneumonia as a rarely diagnosed and published one. We report a case of cryptogenic organizing pneumonia secondary to amiodarone treatment, its clinical course with significant improvement of clinical symptoms within a few days after discontinuation of amiodarone treatment and administration of corticosteroids. Also the infiltrations found in chest X-ray and computed tomography responded well and showed remarkable resolution tendency quickly. During 5 months of corticoid therapy pulmonary abnormalities gradually resolved almost completely and remained equal during the 8 months follow-up after corticoid termination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668958     DOI: 10.1007/s00508-010-1412-3

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  27 in total

Review 1.  Drug-induced bronchiolitis obliterans organizing pneumonia.

Authors:  Gary R Epler
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

2.  Amiodaronoma: an unusual form of amiodarone-induced pulmonary toxicity.

Authors:  Julie Jarand; Andrew Lee; Richard Leigh
Journal:  CMAJ       Date:  2007-05-08       Impact factor: 8.262

Review 3.  Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance.

Authors:  R Sunderji; Z Kanji; K Gin
Journal:  Can J Cardiol       Date:  2000-11       Impact factor: 5.223

4.  Detection of amiodarone-induced pulmonary toxicity in supine and prone positions: high-resolution computed tomography study.

Authors:  Noriko Oyama; Naotsugu Oyama; Hisashi Yokoshiki; Tamotsu Kamishima; Toshikazu Nambu; Hiroyuki Tsutsui; Kazuo Miyasaka
Journal:  Circ J       Date:  2005-04       Impact factor: 2.993

5.  BOOP: an important cause of migratory pulmonary infiltrates?

Authors:  T E King
Journal:  Eur Respir J       Date:  1995-02       Impact factor: 16.671

6.  [Spontaneous remission of an amiodarone-induced pulmonary lesion].

Authors:  M Müller; W Schima; M Weissel
Journal:  Wien Klin Wochenschr       Date:  1997-11-28       Impact factor: 1.704

7.  Bronchiolitis obliterans organising pneumonia in patients taking acebutolol or amiodarone.

Authors:  P Camus; J N Lombard; M Perrichon; F Piard; J C Guérin; F B Thivolet; L Jeannin
Journal:  Thorax       Date:  1989-09       Impact factor: 9.139

Review 8.  Bronchiolitis obliterans organizing pneumonia.

Authors:  G R Epler
Journal:  Arch Intern Med       Date:  2001-01-22

9.  Bronchiolitis obliterans organizing pneumonia: pathogenesis, clinical features, imaging and therapy review.

Authors:  Sara Al-Ghanem; Hamdan Al-Jahdali; Hanaa Bamefleh; Ali Nawaz Khan
Journal:  Ann Thorac Med       Date:  2008-04       Impact factor: 2.219

10.  Bronchoalveolar lavage cell count and differential are not reliable indicators of amiodarone-induced pneumonitis.

Authors:  J A Ohar; F Jackson; P A Dettenmeier; C W Bedrossian; S M Tricomi; R G Evans
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

View more
  1 in total

Review 1.  Benefits and pitfalls of cardiovascular medication in seniors.

Authors:  Hana Matejovska Kubesova; Pavel Weber; Hana Meluzinova; Katarina Bielakova; Jan Matejovsky
Journal:  Wien Klin Wochenschr       Date:  2013-07-12       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.